| Type I IFN signaling mediates NET release to promote Mycobacterium tuberculosis replication and granuloma caseation CS Chowdhury, RL Kinsella, EM Nehls, SK Naik, DS Lane, P Talukdar, ... Biorxiv, 2022.11. 29.518376, 2022 | 6 | 2022 |
| Macrophages and neutrophils express IFNλs in granulomas from Mycobacterium tuberculosis-infected nonhuman primates P Talukdar, BF Junecko, DS Lane, P Maiello, JT Mattila Frontiers in Immunology 13, 985405, 2022 | 6 | 2022 |
| Characterization of AB598, a CD39 Enzymatic Inhibitory Antibody for the Treatment of Solid Tumors AE Anderson, K Parashar, K Jin, J Clor, CE Stagnaro, U Vani, J Singh, ... Molecular Cancer Therapeutics, OF1-OF12, 2024 | 2 | 2024 |
| Psychobiotics: A Restorative Intervention for Lifestyle-Induced Deteriorations of Mental Health A Banerjee, PD Talukdar, T Saha, A Bhattacharya, K Pramanik, ... Brain and Mental Health in Ageing, 445-471, 2024 | 1 | 2024 |
| Type III interferons are expressed in tuberculosis granulomas and can enhance anti-mycobacterial activity of macrophages P Talukdar University of Pittsburgh, 2023 | 1 | 2023 |
| Type III interferons are expressed in tuberculosis granulomas and promote an inflammatory phenotype in macrophages that differs from type I interferon P Talukdar, JT Mattila, BA Fallert Junecko The Journal of Immunology 204 (1_Supplement), 149.15-149.15, 2020 | 1 | 2020 |
| Type 3 interferons expressed in tuberculous granulomas may influence signaling in epithelioid macrophages JT Mattila, P Talukdar, BA Junecko The Journal of Immunology 200 (1_Supplement), 117.25-117.25, 2018 | 1 | 2018 |
| Targeting breast cancer stem cells in ER-positive breast cancer by repurposing the benzoporphyrin derivative verteporfin as a YAP/TAZ small molecule inhibitor PD Talukdar, H Roy, U Chatterji Molecular Biology Reports 52 (1), 1-14, 2025 | | 2025 |
| Type I IFN-mediated NET release promotes Mycobacterium tuberculosis replication and is associated with granuloma caseation CS Chowdhury, RL Kinsella, ME McNehlan, SK Naik, DS Lane, ... Cell Host & Microbe 32 (12), 2092-2111. e7, 2024 | | 2024 |
| 787 AB598, a CD39 inhibitory antibody, promotes immune-mediated tumor control J Clor, K Jin, K Parashar, AE Anderson, L Kates, Y Guan, S Schwager, ... J Immunother 11 (1), A1-A1731, 2023 | | 2023 |
| Inhibiting glycolysis by targeting the enzyme PFKFB3 restricts macrophage anti-mycobacterial activity and neutrophil phagocytosis of Mycobacterium tuberculosis. DS Lane, P Talukdar, BF Junecko, JT Mattila The Journal of Immunology 208 (1_Supplement), 110.03-110.03, 2022 | | 2022 |
| Type III IFNs (IFNλs) expressed in tuberculosis (TB) granulomas enhance anti-mycobacterial activity of macrophages P Talukdar, BF Junecko, JT Mattila The Journal of Immunology 208 (1_Supplement), 50.43-50.43, 2022 | | 2022 |
| Type 1 interferon expression and signaling occur in distinct regions in granulomas during Mycobacterium tuberculosis infection AM Jespersen, BA Junecko, P Talukdar, JT Mattila The Journal of Immunology 204 (1_Supplement), 60.3-60.3, 2020 | | 2020 |
| SIVmac239 infection dysregulates anti-mycobacterial immunity at the granuloma level and contributes to severe tuberculosis in cynomolgus macaques JT Mattila, P Talukdar, A Jespersen, BA Fallert Junecko, R Moriarty, ... The Journal of Immunology 204 (1_Supplement), 248.6-248.6, 2020 | | 2020 |
| Type III interferons are expressed in tuberculosis granulomas and may influence signaling in epithelioid macrophages P Talukdar, JT Mattila The Journal of Immunology 202 (1_Supplement), 62.2-62.2, 2019 | | 2019 |
| Macrophages and neutrophils express IFNλs in granulomas from Mycobacterium tuberculosis-infected nonhuman primates | | |
